Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response

Retrovirology. 2013 Oct 24:10:110. doi: 10.1186/1742-4690-10-110.

Abstract

Background: Differently from HIV-1, HIV-2 disease progression usually takes decades without antiretroviral therapy and the majority of HIV-2 infected individuals survive as elite controllers with normal CD4⁺ T cell counts and low or undetectable plasma viral load. Neutralizing antibodies (Nabs) are thought to play a central role in HIV-2 evolution and pathogenesis. However, the dynamic of the Nab response and resulting HIV-2 escape during acute infection and their impact in HIV-2 evolution and disease progression remain largely unknown. Our objective was to characterize the Nab response and the molecular and phenotypic evolution of HIV-2 in association with Nab escape in the first years of infection in two children infected at birth.

Results: CD4⁺ T cells decreased from about 50% to below 30% in both children in the first five years of infection and the infecting R5 viruses were replaced by X4 viruses within the same period. With antiretroviral therapy, viral load in child 1 decreased to undetectable levels and CD4+ T cells recovered to normal levels, which have been sustained at least until the age of 12. In contrast, viral load increased in child 2 and she progressed to AIDS and death at age 9. Beginning in the first year of life, child 1 raised high titers of antibodies that neutralized primary R5 isolates more effectively than X4 isolates, both autologous and heterologous. Child 2 raised a weak X4-specific Nab response that decreased sharply as disease progressed. Rate of evolution, nucleotide and amino acid diversity, and positive selection, were significantly higher in the envelope of child 1 compared to child 2. Rates of R5-to-X4 tropism switch, of V1 and V3 sequence diversification, and of convergence of V3 to a β-hairpin structure were related with rate of escape from the neutralizing antibodies.

Conclusion: Our data suggests that the molecular and phenotypic evolution of the human immunodeficiency virus type 2 envelope are related with the dynamics of the neutralizing antibody response providing further support for a model in which Nabs play an important role in HIV-2 pathogenesis.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing / immunology*
  • Antigenic Variation
  • Child
  • Child, Preschool
  • Evolution, Molecular*
  • Female
  • Genetic Variation*
  • HIV Antibodies / immunology*
  • HIV Infections / immunology
  • HIV Infections / virology*
  • HIV-2 / genetics
  • HIV-2 / immunology*
  • Humans
  • Infant
  • Infant, Newborn
  • Molecular Sequence Data
  • Sequence Analysis, DNA
  • env Gene Products, Human Immunodeficiency Virus / genetics
  • env Gene Products, Human Immunodeficiency Virus / immunology*

Substances

  • Antibodies, Neutralizing
  • HIV Antibodies
  • env Gene Products, Human Immunodeficiency Virus

Associated data

  • GENBANK/GU983917
  • GENBANK/GU983918
  • GENBANK/GU983919
  • GENBANK/GU983920
  • GENBANK/GU983921
  • GENBANK/GU983922
  • GENBANK/GU983923
  • GENBANK/GU983924
  • GENBANK/GU983925
  • GENBANK/GU983926
  • GENBANK/GU983927
  • GENBANK/GU983928
  • GENBANK/GU983929
  • GENBANK/GU983930
  • GENBANK/GU983931
  • GENBANK/GU983932
  • GENBANK/GU983933
  • GENBANK/GU983934
  • GENBANK/GU983935
  • GENBANK/GU983936
  • GENBANK/GU983937
  • GENBANK/GU983938
  • GENBANK/GU983939
  • GENBANK/GU983940
  • GENBANK/JX219591
  • GENBANK/JX219592
  • GENBANK/JX219593
  • GENBANK/JX219594
  • GENBANK/JX219595
  • GENBANK/JX219596
  • GENBANK/JX219597
  • GENBANK/JX219598
  • GENBANK/JX219599
  • GENBANK/JX219600
  • GENBANK/JX219601
  • GENBANK/JX219602
  • GENBANK/JX219603
  • GENBANK/JX219604
  • GENBANK/JX219605
  • GENBANK/JX219606
  • GENBANK/JX219607
  • GENBANK/JX219608
  • GENBANK/JX219609
  • GENBANK/JX219610
  • GENBANK/JX219611
  • GENBANK/JX219612
  • GENBANK/JX219613
  • GENBANK/JX219614